Disclosures. **C. Jones**, Rebiotix, Inc.: Employee, Salary. **K. Blount**, Rebiotix, Inc.: Employee, Salary. **T. Savidge**, Rebiotix: Grant Investigator, Research grant.

2553. Individual Patient-Level Data Meta-Analysis of Live Attenuated and Inactivated Influenza Vaccine Effectiveness Among US Children, 2013–2014 Through 2015–2016

Jessie Chung, MPH[1]; Brendan Flannery, PhD[2]; Rodolfo Begue, MD[3]; Herve Caspard, MD, ScD[4]; Laurie Demarcus, MPH[5]; Ashley Fowlkes, MPH[2]; Geeta Kersellius, MPH, MBA[5]; Andrea Steffens, MPH[1] and Alicia M. Fry, MD, MPH[1], [1]Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, [2]Centers for Disease Control and Prevention, Atlanta, Georgia, [3]Infectious Diseases, Louisiana State University Health Sciences Center, New orleans, Louisiana, [4]AstraZeneca, Gaithersburg, Virginia and [5]DoD Global, Laboratory-Based, Influenza Surveillance Program, is Defense Health Agency/Armed Forces Health Surveillance Branch, Air Force Satellite Cell, Wright-Patterson AFB, Ohio

Session: 269. Flu and other Vaccines in Children
Saturday, October 6, 2018: 2:00 PM

Background. Quadrivalent live attenuated influenza vaccine (LAIV4) was not recommended for use in the United States for the 2016–2017 and 2017–2018 influenza seasons based on US observational studies of vaccine effectiveness (VE) from 2013–2014 to 2015–2016. We pooled individual patient data on children aged 2–17 years enrolled in 5 US studies during these 3 influenza seasons to further investigate VE by vaccine type.

Methods. Analyses included 17,173 children enrolled in the US Department of Defense Global Laboratory-based Influenza Surveillance Program, US Influenza Vaccine Effectiveness Network, Influenza Incidence Surveillance Project, Influenza Clinical Investigation for Children, and a Louisiana State University study. Participants' specimens were tested for influenza by reverse transcription-polymerase chain reaction (RT-PCR), culture, or a combination of rapid antigen testing and RT-PCR. VE was calculated by comparing odds of vaccination with either inactivated influenza vaccine (IIV) or LAIV4 among influenza-positive cases to test-negative controls and calculated as 100 × (1 − odds ratio) in logistic regression models with age, calendar time, influenza season, and study site (random effect). Patients were stratified by prior season vaccination status in a subanalysis.

Results. Overall, 38% of patients (N = 6,558) were vaccinated in the current season, of whom 30% (N = 1,979) received LAIV4. Pooled VE of IIV against any influenza virus was 51% (95% CI: 47, 54) versus 26% (95% CI: 15, 36) for LAIV4. Point estimates for pooled VE against any influenza by age group ranged from 45% to 58% for IIV and 19% to 34% for LAIV4 during the 3 seasons (Figures 1 and 2). Pooled VE against influenza A(H1N1)pdm09 was 67% (95% CI: 62, 72) for IIV versus 20% (95% CI: −6, 39) for LAIV4. Pooled VE against influenza A(H3N2) was 29% (95% CI: 14, 42) for IIV versus 7% (95% CI: −11, 23) for LAIV4, and VE against influenza B was 52% (95% CI: 42, 60) for IIV and 66% (95% CI: 47, 77) for LAIV4. VE against influenza A(H1N1)pdm09 was lower for LAIV4 versus IIV across all strata of prior season vaccination (Figure 3).

Conclusion. Consistent with individual studies, our pooled analyses found that LAIV4 effectiveness was reduced for all age groups against influenza A(H1N1)pdm09 compared with IIV. This result did not vary based on prior vaccination status.

Figure 1. Adjusted VE of IIV by influenza (sub)type and age group



Figure 2. Adjusted VE of LAIV by influenza (sub)type and age group



Figure 3. Adjusted VE of IIV and LAIV against influenza A/H1N1pdm09 stratified by prior season vaccine exposure



Disclosures. **H. Caspard**, AstraZeneca: Employee, Salary.

2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine

Sybil Tasker, MD, MPH, FIDSA[1]; Vyjayanthi Krishnan, PhD[1]; Stephan Bart, MD[2]; Anvar Suyundikov, PhD[1]; Peta-Gay Booth, MD[2]; Anna Wight O'Rourke, MS[1]; Jianfeng Zhang, PhD[1]; Bertrand Georges, PhD[3] and Scot Roberts, PhD[1], [1]Altimmune, Inc., Gaithersburg, Maryland, [2]Optimal Research, LLC, Rockville, Maryland and [3]Altimmune, Inc., London, UK

Session: 269. Flu and other Vaccines in Children
Saturday, October 6, 2018: 2:00 PM

Background. NasoVAX is a replication-deficient adenovirus-based vaccine designed to express influenza hemagglutinin in nasal epithelial cells when given as a nasal spray. In preclinical studies, NasoVAX was associated with divergent strain protection. Prior preclinical and clinical studies with the vector demonstrated lack of impact from baseline adenovirus immunity.

Methods. Sixty healthy adults were randomized to an A/California 2009-based monovalent NasoVAX formulation at doses of 10^9, 10^{10}, or 10^{11} viral particles or saline placebo, all given as a 0.25 mL nasal spray in each nostril. Subjects were followed for safety, including solicited local and systemic side effects. Immune measures included hemagglutination inhibition (HAI) and neutralizing antibody (MN) at days 1, 15, 29, 90, and 180, and γ-interferon ELISpot at day 1 and 8. A parallel cohort of 20 similar subjects were dosed with Fluzone® injectable influenza vaccine containing an A/California 2009 component and had assessments at the same timepoints. The laboratory was blind to treatment assignment for these comparator samples.

Results. NasoVAX was well tolerated with no serious adverse events and no fever. Solicited symptoms such as nasal congestion, sore throat, and headache did not increase with dose and were not statistically different than placebo. Available immune response data are shown below.

Group	NasoVAX (10^9 vp)	NasoVAX (10^{10} vp)	NasoVAX (10^{11} vp)	Fluzone®	Placebo
Seroprotection Rate at Day 29 (≥1:40 HAI)	80%	100%	100%	95%	53%
(95% CIs)	(51.9%, 95.7%)	(78.2%, 100.0%)	(78.2%, 100.0%)	(75.1%, 99.9%)	(26.6%, 78.7%)
MN Responder Rate at Day 29 (2-fold rise)	40%	47%	73%	70%	0%
(95% CIs)	(16.3%, 67.7%)	(21.3%, 73.4%)	(44.9%, 92.2%)	(45.7%, 88.1%)	(0.0%, 21.8%)
Median ELISpot Day 8 SFC/10^6 PBMC	58.0	12.0	307.5	55.5	0.0
(95% CIs)	(5.31, 110.69)	(0.0, 60.36)	(2.15, 612.78)	(4.12, 106.87)	(0.0, 38.49)

Conclusion. NasoVAX intranasal influenza vaccine was well tolerated and elicited comparable antibody responses and nearly 6-fold higher cellular immune responses than a licensed injectable vaccine.

Disclosures. **S. Tasker**, Altimmune, Inc: Employee and Shareholder, Salary. **V. Krishnan**, Altimmune, Inc.: Employee and Shareholder, Salary. **S. Bart**, Altimmune, Inc.: Research Contractor, fee for research services. **A. Suyundikov**, Altimmune, Inc.: Employee, Salary. **P. G. Booth**, Altimmune, Inc.: Research Contractor, fee for research services. **A. Wight O'Rourke**, Altimmune, Inc.: Employee and Shareholder, Salary. **J. Zhang**, Altimmune, Inc.: Employee and Shareholder, Salary. **B. Georges**, Altimmune, Inc.: Employee and Shareholder, Salary. **S. Roberts**, Altimmune, Inc.: Employee and Shareholder, Salary.

2555. Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children After 13-Valent Pneumococcal Conjugate Vaccination

Melike Yildirim, MS[1] Stephen I. Pelton, MD[2] Pinar Keskinocak, PhD[3] and Inci Yildirim, MD PhD MSc[4,5], [1]School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, [2]Boston University Schools of Medicine and Public Health, Boston, Massachusetts, [3]College of Engineering and Co-Director Center for Health and Humanitarian Systems, Georgia Institute of Technology, Atlanta, Georgia, [4]Rollins School of Public Health, Emory University, Atlanta, Georgia and [5]Pediatric Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia

Session: 269. Flu and other Vaccines in Children
Saturday, October 6, 2018: 2:00 PM

Background. Thirteen-valent-pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the childhood immunization schedule in Massachusetts beginning in April 2010. We evaluated the predictors of vaccine-type (VT) invasive pneumococcal infection (IPD) occurrence despite vaccination.

Methods. Cases of IPD in children <18 years of age were detected through an enhanced surveillance system in MA since 2001. All cases and *Streptococcus pneumoniae* (SP) isolates are submitted to Department of Public Health (MDPH) and parents/physicians are interviewed for confirmation of demographic and clinical data. All available isolates are serotyped by Quellung reaction. Children who received any dose of PCV7 were excluded from this study. We used 4-layer, feed-forward, neural network with back-propagation learning algorithm, random forest algorithm with 150 classification trees, and extreme gradient boosting (XGBoost) algorithm based on boosted trees with over than 200 iterations to make prediction about risk of nonvaccine serotype (NVST) causing IPD.

Results. Overall, 144 IPD cases have been identified between April 1, 2010, and March 31, 2017, and 27 (19%) were VT IPD. Compared with children with complete PCV13 vaccination, IPD among those with incomplete immunization was more likely